Sodium Bicarbonate

Exela Pharma Sciences, LLC has initiated a Class II recall for its 4.2% Sodium Bicarbonate Injection due to out-of-specification arsenic impurities. This event, recall D-0620-2025, impacts nationwide distribution, necessitating immediate supply chain review for procurement directors. The Lenoir, NC facility is under scrutiny, demanding robust remediation and alternative sourcing strategies.

Exela Pharma Sciences LLC has initiated a Class II recall of 103,950 vials of 8.4% Sodium Bicarbonate Injection, USP, due to a lack of sterility assurance. This nationwide recall, impacting critical intravenous medication, necessitates immediate action from procurement, supply chain, and regulatory teams to mitigate patient risk and ensure continuity of supply.